May 14, 2024 4:44pm

Seems to put a damper on expectations?

Earnings: Generation Bio (GBIO) and Precigen (PGEN) <see The Bottom Line>

As I had stated, “let’s not forget about volatility”

A 360-degree review of the who, why, when and what happened in the sector as the market and economics surround your portfolio’s defense or offence.

Never leave an investor uninformed! A trusted source of factual reporting!

The present and future value of RegMed Investors (RMi) NEWS sheds light on the stem, cell and gene therapy sector’s risks to share pricing and the sector’s upside acrobatics and potential downslides.

I write this blog/newsletter about – facts in evidence! 

 

Tuesday: The Dow closed UP +126.60 points or +0.32%, the S&P closed UP +25.26 points or +0.48 % while the Nasdaq closed UP +122.94 points or +0.75%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes rose Tuesday following the release of fresh U.S. economic data, while investors waited for a PPI (inflation) report.

The market’s reaction was I believed IGNORED, as the March wholesale prices reading were revised down to show a 0.1% decline.

  • Traders may also be hesitant to overreact to this report ahead of the more closely followed consumer price index, due to be released Wednesday.

Economic Data Docket: The PPI gained 0.5% from April, higher than the 0.3% that economist had anticipated.

 

RegMed Investors (RMi) Research Note: Q1/24 earnings reporting dates, net losses, cash positions, revenue and runway outcomes … https://www.regmedinvestors.com/articles/13441   

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results … https://www.regmedinvestors.com/articles/11628

 

Advance/Decline (A/D) Line:

  • Tuesday’s advance/decline line at the open was positive with 26 incliner, 6 decliners and 3 flats; ending with a positive close of 19 incliners, 13 decliners and 3 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

Q2/24: 7 positive and 3 negative closes

  • April; 16 negative and 6 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Tuesday, the IBB was up +0.79% and the XBI was up +1%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Tuesday was down -0.20 point or -1.47% at 13.40

 

Tuesday’s Closing Down (10 of 13):

  • Blueprint Medicine (BPMC -$2.59 after Monday’s +$1.35),
  • Alnylam Pharmaceuticals (ALNY -$2.00 after Monday’s -$0.58),
  • Ionis Pharmaceuticals (IONS -$0.53 after Monday’s -$0.28,
  • Agenus (AGEN -$0.39 after Monday’s +$0.60),
  • Adverum Biotechnologies (ADVM -$0.24 after Monday’s -$0.13),
  • Beam Therapeutics (BEAM -$0.21 after Monday’s +$2.76),
  • Lenz Therapeutics (LENZ -$0.19),
  • Sage Therapeutics (SAGE -$0.18),
  • Caribou Biosciences (CRBU -$0.07),
  • Brainstorm Cell therapeutics (BCLI -$0.0479),

Flat (3):

  • Bellicum Pharmaceuticals (BLCM) – dropped)
  • Voyager Therapeutics (VYGR)
  • Harvard Apparatus RT (OTCQB: HRGN $0.00 after Monday's +$0.07),

Tuesday’s Closing Up (10 of 19):

  • BioLife Solutions (BLFS +$1.77 after Monday’s +$1.12),
  • Generation bio (GBIO +$0.70 after Monday’s -$0.15),
  • Intellia Therapeutics (NTLA +$0.31 after Monday’s +$0.96),
  • Prime Medicine (PRME +$0.24 after Monday’s +$0.81),
  • Mesoblast (MESO +$0.22 after Monday’s -$0.38),
  • Solid Biosciences (SLDB +$0.21 after Monday’s -$0.64),
  • Cellectis SA (CLLS +$0.07)
  • Fate Therapeutics (FATE +$0.07),
  • Regenxbio (RGNX +$0.06),
  • CRISPR Therapeutics (CRSP +$0.06),

 

Q2/24 – May

  • Tuesday closed positive with 19 incliners, 13 decliners and 3 flats

 

The BOTTOM LINE:  The cell and gene therapy stocks stayed positive yet diminished in its advance/decline line after the PPI inflation reading; while the overall market moves were contained as the March wholesale prices reading was revised down to show a -0.1% decline.

  • Traders may also be hesitant to overreact to this report ahead of the more closely followed consumer price index, due to be released Wednesday.

On Wednesday eyes will be on April's Consumer Price Index (CPI) data and April retail sales.

  • CPI is expected to rise 3.4% year over year while the core reading, which strips out food and energy, is expected to increase 3.6%.

Today:

  • Generation Bio (GBIO) reported a Q1/24 net loss of -$74.5 M or -$1.12 per share with a cash position of S233.9 M, ATM usage of $3.8 M, $4,059 K revenue and a runway until 2H/27
  • Precigen (PGEN) reported a Q1/24 net loss of -$23.7 M or -$0.10 per share with a cash position of $44.8 M, revenue of $800 K M and a runway until Q3/2024

Reporting: https://www.regmedinvestors.com/articles/11628   

 

The top three (3) performing in the session:  

  • Tuesday: BioLife Solutions (BLFS), Generation Bio (GBIO (GBIO) and Intellia Therapeutics (NTLA)
  • Monday: CRISPR Therapeutics (CRSP), Beam Therapeutics (BEAM) and Blueprint Medicine (BLMC)

The worst three (3) in the session:

  • Tuesday: Blueprint Medicine (BLMC), Alnylam Pharmaceuticals (ALNY) and Ionis Pharmaceuticals (IONS) 
  • Monday: Solid Biosciences (SLDB), Alnylam Pharmaceuticals (ALNY) and Mesoblast (MESO)

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.